Eli Lilly and Co. on Thursday warned against use of its popular diabetes and weight loss drugs Mounjaro and Zepbound for “cosmetic” reasons. The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages, making it more difficult for those with medical needs to obtain them.
The major pharmaceutical company says its drugs, also known as GLP-1s, are not meant for those without obesity or Type 2 diabetes.
